Hainan Simcere Pharmaceutical Co. Ltd. has prepared bicyclic compounds acting as fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.
Insilico Medicine Inc. has identified compounds acting as tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer and metabolic disease.
Oncozen Co. Ltd. has patented new proteolysis targeting chimera (PROTAC) compounds comprising a heat shock protein 90 (HSP90) binding moiety covalently bound to hepatocyte growth factor receptor (HGFR; MET) targeting moiety through a linker.
Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors arising from chromaffin cells chromaffin cells in the adrenal medulla or extra-adrenal paraganglia, respectively.
Actinium Pharmaceuticals Inc. has received FDA clearance of an IND application to study Iomab-ACT for targeted conditioning prior to a bone marrow transplant (BMT) in patients with sickle cell disease.
Researchers from the Chinese Center for Disease Control and Prevention detailed the discovery of novel aromatic heterocycle substituted aminamidine derivatives (AADs) for the treatment of Necator americanus infection (hookworms).
Chemotherapy usually induces cachectic muscle loss through different mechanisms. Among these, oxidative stress is known to decrease protein synthesis and increase proteolysis leading to muscle atrophy.
Medannex Ltd. has been awarded an Innovate UK grant to fund a £313,000 (US$403,000) project developing a new treatment for pediatric osteosarcoma. Innovate UK will fund £231,000 (US$297,000) of the project costs, with the remainder financed by Medannex.
Half of the individuals with genital herpes simplex virus (HSV) infection experience several recurrence episodes per year, especially if the causative agent is HSV type 2 (HSV-2). Standard-of-care viral DNA polymerase inhibitors are not fully effective in preventing recurrences and managing symptoms.
Researchers from Shuttle Pharmaceuticals LLC and Georgetown University have described the in vitro and in vivo profile of SP-1-303, designed as a dual-function histone deacetylase (HDAC) inhibitor and ataxia-telangiectasia mutated protein (ATM) activator, in breast cancer models.
RSS
